Shan Zhang

Shan Zhang

Auto-generated profile, based on publicly available information

Shan Zhang

State Key Laboratory of Complex Severe and Rare Diseases, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in The Journal of Dermatology
Verified
Journal Article
Closed access
SZShan Zhang
Shan Zhang
QZQing‐Li Zhu
Qing‐Li Zhu
MXMeng‐Su Xiao
Meng‐Su Xiao
Jie LiuJie Liu
Jie Liu

2 May 2022 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
SZShan Zhang
Shan Zhang
Jie LiuJie Liu
Jie Liu
Citation: Zhang S, Liu J. Syringocystadenoma Papilliferum and Eccrine Poroma Arising in Verrucous Epidermal Nevus: A Case Report and Multidimensional Skin Imaging Evaluation. Dermatol Pract Concept. 2022;12(2):e2022087. DOI: https://doi.org/10.5826/dpc.1202a87 Accepted: October 4, 2021; Published: April 2022 Copyright: ©2022 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: This work is supported by grants from the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2019XK320024). Competing interests: None. Authorship: All authors have contributed significantly to this publication Corresponding author: Jie Liu, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, China 100730. Email: Liujie04672@pumch.cn Keywords : verrucous epidermal nevus, syringocystadenoma papilliferum, eccrine poroma, dermoscopy, high-frequency ultrasound This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

24 January 2024 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Open access
SZShan Zhang
Shan Zhang
Yu-Kun WangYu-Kun Wang
Yu-Kun Wang
JWJuncheng Wang
Juncheng Wang
Jie LiuJie Liu
Jie Liu
Prepubertal girls are one of the vulnerable populations of vulvar lichen sclerosus (VLS), which results in a decreased quality of life and increases risk of vulvar cancer. But the therapeutic effects of traditional topical remedies are unsatisfactory in some pediatric patients. 5-Aminolevulinic acid photodynamic therapy (ALA-PDT) is an effective treatment for refractory VLS patients, but no study has been conducted in child patients. The patients included in this study underwent three sessions of ALA-PDT at 2-week intervals. All patients were evaluated for objective clinical appearances and subjective symptoms quantitatively. Statistical analysis comparing parameters at baseline and after three-time ALA-PDT was performed. A total of seven VLS girl patients were included in this study. Both primary objective appearances (lesion size and depigmentation) and subjective symptoms (itching and burning pain) were improved remarkably after the third treatment. Besides, adverse effects, mainly as pain and post-treatment edema, were mild and could be tolerated. ALA-PDT is an effective and safe therapeutic option for VLS girl patients. Compared with adult patients, the symptoms resolved more quickly in child patients.

1 January 2024 in Dermatologic Therapy
Verified
Journal Article
Open access
ZPZhiyu Pang
Zhiyu Pang
SZShan Zhang
Shan Zhang
ZLZhaorui Liu
Zhaorui Liu
WZWei Zhang
Wei Zhang
Jie LiuJie Liu
Jie Liu
Brentuximab vedotin (BV) has been approved for CD30‐positive cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment in China. However, real clinical practice is still limited. We aim to retrospectively review our experience with BV in a cohort of Chinese patients with CTCL, focusing on its efficacy and safety. We included 17 CTCL patients treated with BV at Peking Union Medical College Hospital from January 2021 to June 2024, including 12 with mycosis fungoides (MF)/Sézary syndrome (SS) and five with primary cutaneous anaplastic large‐cell lymphoma (pc‐ALCL). Patients had previously received a median of three treatment regimens (including acitretin, interferon, methotrexate, histone deacetylase inhibitors, phototherapy, radiotherapy, and chemotherapy). Sixteen patients received BV treatment at an initial dose of 1.8 mg/kg intravenously every 3 weeks, either as monotherapy (7/17) or in combination with gemcitabine, chidamide, or multiagent chemotherapy. The median treatment cycle has six cycles. Two patients received BV as the last treatment before undergoing allogeneic stem cell transplantation (alloSCT). The overall response rate (ORR) was 71% (13/17), with 18% (3/17) achieving complete remission (CR). In the MF/SS group, the ORR was 58% (7/12), while in the pc‐ALCL group, it was 100% (5/5). Adverse events (AEs) were observed in 12 patients, including peripheral neuropathy (PN) in three cases, fever in six cases, neutropenia in three cases, exfoliative dermatitis in two cases, and abnormal liver function in one case. Only one patient experienced ≥ Grade 3 AEs. Based on clinical experience in our center, BV, either as monotherapy or combined with chemotherapy, showed a good response in the treatment of advanced CTCL patients with good tolerability.

17 April 2026 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SZShan Zhang
Shan Zhang
ZPZhiyu Pang
Zhiyu Pang
JLJie Liu
Jie Liu